The bundling of clinical expertise in centralised treatment centres is considered an effective intervention to improve quality and efficiency of acute stroke care. In 2010, 8 London Trusts were converted into Hyper Acute Stroke Units. The intention was to discontinue acute stroke services in 22 London hospitals. However, in reality, provision of services declined only gradually, and 2 years later,
| INTRODUCTION
Policymakers are focusing considerable efforts on improving the quality and efficiency of hospital care (Scott, 2009) . One effective intervention for triggering change is the introduction of centralised treatment centres, where the bundling of clinical expertise translates into enhanced service delivery, characterised by efficiently applied processes and improved clinical outcomes. Successful centralisations are documented in cancer care (Gooiker et al., 2011; Lemmens et al., 2011) , with specialist units leading to reduced 30-day mortality and overall costs (Gooiker et al., 2011; Lemmens et al., 2011) . The primary theory underlying centralisation is the physician/unit-volume effect (Schmidt et al., 2010; Freeman, Wang, Curtis, Heidenreich, & Hlatky, 2012; Svendsen, Ehlers, Ingeman, & Johnsen, 2012; Halm, Lee & Chassin, 2002) , whereby clinical staff enhance their ability to perform specialist tasks through continuous repetition, which leads to better patient outcomes. Although the effectiveness of centralisation for surgical interventions is well documented, little is known about its effectiveness in acute settings (Kanhere, Kanhere, Cameron, & Maddern, 2012) .
with the objective of improving stroke processes and outcomes, as well as saving costs in the long run (Healthcare for London, 2008) . The identification of Trusts that should become HASUs followed a modelling exercise (Fulop et al., 2013) , addressing not only population need and configuration requirements, but also an ambulance travelling time of maximum 30 min to the closest facility, given any possible stroke patient location within the London catchment area. All HASUs are equipped with stroke-specialised staff that provide 24/7 stroke care for patients, covering the first 72 hr of the acute stroke episode. Following 72 hr, stroke patients will either be directed to a stroke unit based near their residence, which in many cases is located in a non-HASU Trust, or will be discharged depending on medical needs.
Several empirical studies investigated the effectiveness of centralised stroke care in England (Liu et al., 2011; Fulop et al., 2013; Hunter et al., 2013; Morris et al., 2014; Ramsay et al., 2015) . Early effects showed increased thrombolysis rates (up 12% postpolicy), discharge to home rates (up 35%), and reductions in 30-day mortality rates (down 6%; Liu et al., 2011 ) and interpreted as a direct effect of centralisation. The method used in the study was a before and after comparison of crude rates that were not adjusted for patient case-mix and based on data from one HASU Trust. Further methodological limitations relate to the isolation of policy effects from general improvements in stroke care and nonadjustment for prepolicy performance heterogeneity between Trusts. In particular, some Trusts that eventually transformed into HASUs already provided leading stroke services, for example, thrombolysis treatments in the King's College London Trust, whereas other HASUs had to be newly built and subsequently showed low levels of prepolicy engagement in similar processes. As a result, the observed jump in thrombolysis rates and mortality could be more prominent in Trusts that had lower baseline experiences. Hunter et al. (2013) conducted a before and after cost-effectiveness analysis of the stroke policy in London, with a particular focus on time trends in mortality and length of stay. The study used Cox Proportional hazards and Weibull survival analysis to evaluate changes in outcome and cost. According to the findings of the study, the reorganisation led to improved survival rates illustrated by Kaplan-Meier survival curves, fewer overall deaths, and a cost reduction per stroke patient of £811. A variety of data sets were used, capturing a subsample of stroke patients in London, including the South London Stroke Register and information from two hospitals based in North London. Similar to Liu et al. (2011) , findings are therefore not representative of the treatment effect on the whole stroke patient population in London. Morris et al. (2014) provided the first impact evaluation on the centralisation approach implemented in London as well as Greater Manchester. Difference-in-difference regression methods were used to compare trends in outcomes between London, Greater Manchester and the rest of England. The method accounted for time trends and was conducted at the hospital level, using patient-level records from the HES database, and focussed on all stroke patients living in urban areas in England. The study compared area-wide changes in the whole of London to changes that occurred in the rest of England, and findings supported previously established improvements in outcomes, with significant decreases found for 30-day mortality rates (−1.3%) and length of stay (−1.4 days). However, the study has limitations. The use of the classical difference-in-difference design averages provider performance in London and compares it to changes in the average performance within the rest of England. Morris et al. (2014) failed to address the differential impact on stroke patients in London, given that non-HASUs continued to provide acute stroke care. Even though the method allowed for estimates of the area-wide impact of the policy, it provided no insight into heterogeneity of implementation practice between providers. In fact, deviation from guidelines by some providers could undermine efforts of quality improvements and subsequently dilute previously reported area-level treatment effects.
In summary, past research failed to consider the impact of possible policy deviation by non-HASUs that continued to provide acute stroke treatment. To understand the potential impact of differential treatment received by stroke patients in London, an impact evaluation with two treatment groups is required. The methodological expansion in this study provides policymakers with a crucial insight into the performance variation between HASUs and non-HASUs in London. We include all Trusts that treated at least one patient per quarter. For some Trusts and quarters, we have missing values in our data set, that is, zero patients or missing values for some variables, which may be an indication of no stroke patients being treated or potentially poor coding practice that could impact our results. To avoid that the control group, rest of England, is driven by any changes that occurred through the area-wide stroke policy framework in Greater Manchester, eight Trusts located in the Greater Manchester catchment area are excluded from this study. We also exclude the Epsom and St. Helier University Hospital NHS Trust, because of their location on the periphery of Greater London, it was unclear whether they should be assigned to treatment or control group.
| DATA
We use Trust-level data, aggregated from the patient-level for all patients with a primary diagnosis of stroke, which was obtained from the HES database. Our final data set was based on "super-spells," that is, linked continuous inpatient spells that hold information on patient demographics and treatment for the period between hospital admission and discharge. By definition, super-spells are constructed from "spells" that are separated by less than 2 days, which avoids double counting of patients in case of repatriation to a regular stroke unit in a non-HASU Trust following an acute care "spell" at a HASU Trust. Stroke was defined based on International Classification of Disease, 10th revision codes-I61 (intracerebral haemorrhage), I62 (other nontraumatic intracranial haemorrhage), I63 (cerebral infarction), and I64 (stroke, not specified as haemorrhage or infarction). Patients with a primary diagnosis of subarachnoid haemorrhage are excluded, as this diagnosis was not part of the implemented hyper acute stroke care pathway in London.
We focus on seven stroke specific processes and outcome measures, chosen to cover different critical points in the quality of stroke care along the medical pathway. The measures are based on findings of Palmer, Bottle, Davie, Vincent, and Aylin (2013), which investigated the feasibility of using HES to derive measures for an evaluation of quality of stroke care at the Trust level. Assessed process and outcome measures are 24 hr brain scan rate; thrombolysis treatment rate; rate of patients suffering from hospital acquired aspiration pneumonia; 7-day and 30-day in-hospital mortality rate; rate of patients discharged to their usual place of residence within 56 days of admission; and 30-day emergency readmission rates. Table 1 includes a definition of measures and Table 2 summary statistics.
We control for average Trust-specific covariates, patient age, Charlson index, gender ratio, and hospital transfers rate. The transfer rate describes the proportion of patients coming from another A&E department before receiving acute stroke care. Time invariant regional variation of dependents is captured with dummy variables for seven separate English regions (North East, North West, Yorkshire and the Humber, East Midlands, West Midlands, East of England, South East Central, South Central, and South West).
| ECONOMETRIC FRAMEWORK
To evaluate the intervention, we use a difference-in-difference analysis (Ashenfelter & Card, 1985 )-a widely used tool for causal inference in health policies (Propper, Whitnall, Sutton, & Windmeijer, 2008; Wooldridge, 2002) . Following a Note. Definitions and inclusion/exclusion criteria are adopted from Palmer et al. (2013) . HES = hospital episode statistics, ICD-10 = International Classification of Disease, 10th revision, OPCS = Classification of Intervention and Procedures. similar specification by Marini, Miraldo, Jacobs, and Goddard (2008), we estimate a difference-in-difference model that uses two-treatment groups, HASUs and London non-HASUs. We assume a constant difference between the two treatment groups and Trusts in the rest of England given the absence of an intervention, as well as parallel trends in the process and outcome variables before the policy intervention. The main model of our difference-in-difference regression analysis is specified as:
The dependent variable Y jt represents one of seven process or outcome indicators, in quarter t and Trust j. For the first treatment group, N j takes the value of one if the Trust is a non-HASU in London and zero otherwise. For the second treatment group, H j takes the value of one if the Trust is a HASU and zero otherwise. Both variables are time invariant and capture systematic permanent differences between either the first or second treatment group and the control group and the other treatment group. The coefficient estimate of β 1 presents the differences in outcomes of non-HASU Trusts in London compared to the rest of England and HASU Trusts, whereas β 2 indicates the differences in outcome of HASUs compared to the rest of England and non-HASU Trusts, for reasons unrelated to the reorganisation. Morris et al. (2014) to compare changes in 30-day mortality rates and length of stay for all London Trusts (HASUs and non-HASUs) to the control group, rest of England, using difference-in-difference estimators with random effects. We acknowledge that previous findings may not be fully replicable due to several reasons. First, Morris et al. (2014) performed analyses at the hospital level using patient-level data, whereas our analysis is restricted to aggregate data at the Trust level. Second, we estimate the treatment effect of centralisation in London compared to a control group comprising of all patients admitted to Trusts within the rest of England, but excluding Greater Manchester, Morris et al.'s evaluation was confined to patients living in urban areas. Finally, our study uses in-hospital mortality data derived from patient records, whereas Morris et al. (2014) used mortality data on all deaths including those that occurred outside of hospital. In combination, these differences may lead to significant variations in replicating previous results. The difference-in-difference model is specified as:
where the dummy variable L j takes the value of one if the Trust is located in London and zero otherwise We assess the validity of the control group with a specification that compares HASUs and non-HASUs in London to a control group containing Trusts of seven English metropolitan areas (Birmingham, Bristol, Leeds, Liverpool, Newcastle, Sheffield, and Southampton). We further perform Hausman model specification tests and performed a lead analysis to test the validity of the parallel trends assumption, a prerequisite of the difference-in-difference methodology.
| RESULTS
We identify 678, 968 patients with a primary diagnosis of stroke in England, over the observation period. The number of quarterly recorded strokes increased throughout and is 12.4% higher in quarter 32 compared to quarter 1. As shown in Figure 1 , the proportion of London stroke patients admitted to Trusts with HASU post-reorganisation and Trusts with non-HASUs post-reorganisation is evenly split at approximately 50% before the implementation of the centralisation policy. Immediately after the policy introduction, admission rates started to diverge; and we observe a gradual increase in admissions to HASUs and a decrease in admissions to non-HASUs. Our data show a levelling effect that occurred in quarter 23, beyond which admissions to HASUs account for about 85% of all stroke admissions in London.
Appendix A plots weighted time trends of dependent variables over the study period. We find that stroke processes and outcome measures improved across England. In London, weighted rates closely follow the time trend of HASUs, indicating that the performance in HASUs is the main driver for performance observed in the London area.
| Results from main model specification (1)
Table 3 provides estimates of the difference-in-difference analysis using two treatment groups and comparing them to performance recorded in Trusts based in the rest of England and the other treatment group, respectively. The number of observations used per analysis was 4,665. For some outcome measures, we reject the random effect specification based on the Hausman test. For the estimations of a panel data model with fixed effects, all time invariant variables were omitted. We present results of the fixed effect specification for the models that failed the Hausman test in Appendix B.
According to the coefficient estimate of T t , we find an improvement in stroke care over time that is unrelated to the reorganisation. Across all English Trusts, stroke processes were higher in the quarters after the reorganisation, with 21.1% more patients scanned within 24 hr of hospital admission and 3.9% more patients receiving thrombolysis. Seven-day mortality and 30-day mortality was significantly lowered by 1.9% and 3.7%, respectively. The rates for aspiration pneumonia, discharge to usual place of residence and 30-day emergency readmission, were significantly higher in quarter 17 to 32 compared to the prepolicy period. An additional 0.4% of patients experienced aspiration pneumonia, 6.9% more patients were discharged to their usual place of residence, and 1.3% more patients were readmitted within 30 days of discharge.
On the basis of the coefficient estimates of N j (HASU) and H j (non-HASU), we cannot generally identify underlying time-invariant differences in processes and outcomes between the two treatment groups and the control group, except that London non-HASUs have 5.2% higher aspiration pneumonia rates across all quarters and have 2.7% higher 7-day mortality rates. London HASUs have 3.7% higher 7-day mortality rates and 5.0% higher 30-day mortality rates. No other underlying differences between HASU, non-HASU, and the rest of England are found.
Following the assumption of heterogeneous policy effects, that is, London non-HASUs continued the provision of care for a small proportion of the stroke population, the DiD coefficient of interest, DiD (non-HASUs) is significantly smaller for both processes, aspiration pneumonia and discharge to usual place of residence, and significantly larger for both mortality rates and readmission rates, in the period post-reorganisation. Our findings indicate that 24-hr scan rates are lower by 15.0% in non-HASUs compared to HASUs and Trusts in the rest of England; however, our estimates Note. The Hausman test was used to determine the preferred model effect; fixed effect models omit time invariant variables. HASUs = Hyper Acute Stroke Units; non-HASUs = non-Hyper Acute Stroke Units. Significant coefficient estimates are highlighted in bold.
*Indicates that the variable has robust impact on dependent variable at 10% significance level.
**Indicates that the variable has robust impact on dependent variable at 5% significance level.
***Indicates that the variable has robust impact on dependent variable at 1% significance level.
highlight no policy effect for HASUs when compared to trends in non-HASUs in London and the rest of England. Thrombolysis treatment rates show an opposing effect for HASUs and non-HASUs, with a significant decrease of 4.0% in non-HASUs and a significant increase of 1.9% in HASUs. Further policy effects for patients admitted to London non-HASUs are a 1.9% rise in 7-day mortality rate, a rise in 30-day mortality rate by 2.5%, a 1.7% decrease in aspiration pneumonia rates, a 7.0% decrease in rates of discharge to usual place of residence, and a 1.3% increase in readmission rates. Except for three indicators, there is no effect for HASUs, but importantly, there are negative effects on outcomes and processes for London non-HASUs. This finding suggests that the reorganisation of stroke care led to significantly different policy effects for patients admitted to HASUs and non-HASUs in London. The estimates of the regional dummies show significant variation for 7-day and 30-day mortality rates across English regions.
| Alternate specifications and sensitivity analyses
Our results confirm a reduction in length of stay previously stated by Morris et al. (2014; see Appendix C) ; however, we find no significant effect of centralisation on 30-day in-hospital mortality. This is likely to be caused by limitations of our data, namely, the use of aggregate-level data, inclusion of all patients regardless of whether their place of residence is in rural or urban areas, and the use of 30-day in-hospital mortality, as compared to mortality that includes deaths outside the hospital.
Results from sensitivity analysis, comparing changes in London HASU and non-HASU Trusts to a control group that composes of seven English metropolitan areas, show no significant policy effects on 7-day or 30-day in-hospital mortality for HASUs and non-HASU Trusts in London (Appendix D). A lead analysis showed no significant results and suggests that the common trends assumption is fulfilled, with table in Appendix E. Estimates of weighted versus unweighted analyses is presented in Appendix F and show only slight variations.
| DISCUSSION AND POLICY IMPLICATIONS
The intention of stroke care centralisation in London was to increase provision of stroke processes and improve outcomes, while containing costs (Healthcare for London, 2008) . Our results show that this policy objective was partly achieved by increasing rates of thrombolysis treatment for patients admitted to HASUs. However, we find that approximately 15% of patients still receive acute stroke care in London non-HASU Trusts and estimates of the difference-in-difference analysis suggests that those patients are less likely to receive stroke-specific processes and are experiencing worse outcomes. This is the first study to evaluate the impact of stroke service centralisation in London, addressing heterogeneity in provider performance that was masked by previous studies.
The objective of centralised stroke care in London was to provide acute stroke services for the first 72 hr to patients in eight dedicated London HASUs, leading to the expectation of a reduction in patients receiving treatment in London non-HASU Trusts. Our findings could be explained by a number of factors. First, it could be at least partly explained by variation in coding practice, in particular the miscoding of acute and rehabilitation stroke patients within HES. Recorded stroke patients in non-HASUs could be rehabilitation patients who naturally would not receive processes and are also more likely to experience worse health outcomes as they tend to be sicker compared to patients that are discharged after their acute episode. However, we conducted our analysis at the "super spells" level, which should address the issue of repatriation and potential double counting of stroke patients. Second, although London non-HASUs have no financial incentive in treating stroke patients, our results may indicate selection bias at non-HASU level due to unobservable differences in patient complexity. For example, non-HASUs in London could end up treating sicker patients with multiple life threatening conditions that may preclude transfer to a HASU. Morever, stroke cases treated in non-HASUs could be diagnosed with delay, because sometimes strokes present in complex multimorbid patients and symptoms are difficult to read. Depending on the length of the delay, patients may not be suitable for transfer into a HASU upon diagnosis. Despite adjusting for comorbidities by using the Charlson index, age, and other indicators of patient complexity, HES does not allow adjusting for severity of stroke. A stroke specific measure might have been better at identifying patients clinically unfit for transportation. Lastly, and keeping the above alternative explanations in mind, our results could indicate differences in quality of care received at London HASU and non-HASU Trusts. Poorer quality of care, potentially resulting from factors such as lower availability of specialist stroke staff, diagnostic equipment or treatments, may have led to non-HASU patients being less likely to receive stroke specific processes, 24 hr brain scans and thrombolysis treatment, and being more likely to die within 7 and 30 days.
Our study has limitations. The use of HES data relies largely on the consistency of good quality coding practice. A previous study has shown that up to 16% of all stroke patients are missed when compared to independent hospital stroke registers (Barer & Cassidy, 2014) . However, the same study also found that the Stroke Improvement National Audit Programme omitted 30% of all stroke patients, highlighting that of the two widely used sources for stroke policy evaluations, HES may be the more appropriate data source. In a recent study by Li and Rothwell (2016) , systematic variation in coding practice of stroke patients between the weekday and weekend was highlighted. Even though the study has limited generalisability to the whole population due to its use of data from nine general practices, it flags up potential issues surrounding the quality of administrative data sets and its biases that could affect our estimates in unknown magnitude and direction. However, our study uses a tighter definition of stroke; and we restricted our analysis to emergency admissions, which may help to reduce bias. In this study, we were not able to adjust for the type of stroke, which could bias performance of thrombolysis treatment rates and be a predictor for stroke outcomes. However, previous studies reported high inconstancies in stroke coding across English hospitals (Britton et al., 2012) , which could introduce an additional bias into the analysis if different types of stroke were admitted to the two treatment groups and the control groups in a nonrandom way. Lastly, the introduction of performance targets in relation to clinical processes over the study period may have provided incentives to improve coding of stroke processes, though that would apply to the whole of England.
As shown by previous studies, the centralisation of stroke care in London led to a step change in quality improvement, with processes and outcomes across London as a whole being consistently favourable to rates observed in the rest of England. The provision of centralised stroke care in London is therefore leading in the country, and improvements in London may have translated into learning for other service centralisations. However, although the majority of stroke patients received care in the anticipated clinical pathway, our findings show that the London stroke model would benefit from further exploration into reasons for why approximately 15% of stroke patients still received care within London non-HASU Trusts and causes of poorer processes and outcomes for those patients. For example, one opportunity could be the revision of the London hub-model performance through joint collaboration between the three London Sustainability and Transformation Plans, and to develop strategies on how to drive further improvements in London and derive learning that could benefit other areas. Future research could explore the effectiveness of small-scale local policies, which will help to develop an understanding of initiatives that could run in parallel to current efforts and potentially trigger further improvements of stroke care on a national scale.
In this study, we found evidence to suggest underlying heterogeneity in processes and outcomes between providers following the introduction of an area-level centralisation of acute stroke care services in London, but we are not able to fully determine the reasons underlying such variation. Although the provision of stroke care has improved significantly across the whole of England, with services in London remaining one of the best in the country, a renewed policy engagement into the London stroke model could lead to further improvements in processes and outcomes, ultimately affecting peoples' lives.
